Skip to content
National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
Division of Cancer Prevention logo
Home Site Map Contact DCP
Programs & Resources

Prostate and Urologic Cancer Research Group

Programs and Projects

Bladder Cancer Clinical Trials - University of Wisconsin (Multicenter Sites)

Agent: Soy Isoflavones (Genistein)
Contact: Howard Bailey, MD
DCP Program Director: Joe Tangrea, MPH, PhD

The purpose of this study is to evaluate the potential of Genistein, a soy isoflavone, as a chemopreventive agent for bladder cancer. Individuals who have been recently diagnosed with a new bladder tumor or recurrent bladder tumor and will be undergoing a cyctoscopy and transuretheral resection of bladder tumor (TURBT) or partial/complete removal of the bladder may be eligible to participate in this study. Those taking part in the study will receive soy isoflavones (Genistein) or placebo for several weeks immediately before transuretheral resection of bladder tumor (TURBT) or partial/complete removal of the bladder. The study is being conducted at the University of Wisconsin Comprehensive Cancer Center and several other study sites through the University of Wisconsin Clinical Trials Consortium. This sudy is now closed to accural.

[This is a phase 2 randomized double-blind placebo controlled multicenter trial of soy isoflavones (Genistein) compared to placebo for the prevention of bladder cancer. Patients recently diagnosed with new or recurrent disease of any clinical stage who are candidates for either subsequent cystoscopy/transurethral resection of bladder tumor (TURBT) or complete or partial cystectomy will receive 14 - 21 days of study medication. Histologic diagnosis is not required for enrollment. Participants should have no evidence of distant metastasis.]